NRx Pharmaceuticals (NASDAQ:NRXP) Issues Quarterly Earnings Results

NRx Pharmaceuticals (NASDAQ:NRXP) announced its quarterly earnings data on Friday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.09), Zacks reports. The firm had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.33 million.

NRx Pharmaceuticals Trading Down 2.1%

Shares of NASDAQ NRXP traded down $0.07 during mid-day trading on Friday, hitting $3.27. The company had a trading volume of 1,124,669 shares, compared to its average volume of 1,198,563. The company has a market capitalization of $118.47 million, a PE ratio of -3.00 and a beta of 2.18. The firm has a 50-day simple moving average of $3.80 and a two-hundred day simple moving average of $2.95. NRx Pharmaceuticals has a one year low of $1.62 and a one year high of $5.05.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on NRXP. Wall Street Zen lowered NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 price target on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. BTIG Research dropped their price objective on NRx Pharmaceuticals to $10.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 5th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a report on Monday. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $34.50.

Institutional Investors Weigh In On NRx Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. State Street Corp lifted its stake in shares of NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after buying an additional 10,700 shares during the last quarter. Two Sigma Investments LP grew its position in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after acquiring an additional 20,880 shares during the last quarter. Geode Capital Management LLC raised its position in NRx Pharmaceuticals by 17.8% in the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock valued at $593,000 after purchasing an additional 33,004 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares during the period. Finally, Commonwealth Equity Services LLC bought a new stake in shares of NRx Pharmaceuticals during the 4th quarter valued at about $994,000. 4.27% of the stock is currently owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.